Recent analyses of large CMML cohorts indicate that TET2 mutations without concurrent ASXL1 mutations (ASXL1WT/TET2mut) confer a favorable impact on overall survival (OS) (2, 3). Here, ASXL1 is linked to chronic myelomonocytic leukemia.